[SCHEDULE 13G] Regen BioPharma Inc SEC Filing

Rhea-AI Filing Summary

Quick Capital, LLC reported beneficial ownership of 3,320,000 shares of Regen BioPharma, Inc. common stock, representing 9.9% of the outstanding class. The filing states Quick Capital has sole voting and sole dispositive power over all shares reported and identifies the filer as a Wyoming LLC with its business address in Miami, FL.

The statement is a passive Schedule 13G disclosure certifying the shares were not acquired to change or influence control of the issuer. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and no shared voting or dispositive powers are disclosed.

Positive

• Material ownership disclosed: 3,320,000 shares representing 9.9% of the class.
• Sole control clarity: Quick Capital reports sole voting and sole dispositive power over the shares.
• Passive filing: The filer classifies the statement as a Schedule 13G and certifies the position is not for changing control.

Negative

• None.

Insights

Securities Analyst

TL;DR: A passive investor discloses a near-10% stake with sole voting and dispositive power—material ownership but no stated intent to control.

Quick Capital, LLC’s reported 9.9% stake is material because it approaches double-digit ownership that often draws investor attention. The filing clearly states sole voting and dispositive power for all 3,320,000 shares, which means Quick Capital can unilaterally vote and sell these shares. The Schedule 13G classification and the certification language indicate the position is presented as passive, not seeking to change control. For investors, the key implications are transparency about a significant holder and clarity that no coalition or group is reported.

Corporate Governance Expert

TL;DR: Governance impact is limited by the filer’s passive claim, but sole voting power at 9.9% warrants monitoring.

The disclosure shows no shared voting arrangements or group membership and explicitly disclaims acquisition for control purposes, consistent with a Schedule 13G passive filing. Sole voting power concentrated in one entity near 10% can influence shareholder votes if aligned with others, yet the filing contains no indication of activist intent or planned governance changes. This is a material ownership disclosure for governance assessment but contains no immediate red flags or specified governance actions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

REGEN BIOPHARMA, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

75886M300

(CUSIP Number)

09/10/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 75886M300

1

Names of Reporting Persons

Quick Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

WYOMING

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,320,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,320,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9.90

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: LLC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REGEN BIOPHARMA, INC.
(b)	Address of issuer's principal executive offices: 4700 Spring Street Suite 304 La Mesa, CA 91942
Item 2.
(a)	Name of person filing: Quick Capital, LLC
(b)	Address or principal business office or, if none, residence: 66 West Flagler Street 900- #2292 Miami, FL 33130
(c)	Citizenship: Wyoming
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 75886M300
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,320,000 shares of Common Stock.
(b)	Percent of class: 9.9% of the outstanding shares.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,320,000 shares of Common Stock.
	(ii) Shared power to vote or to direct the vote: none
	(iii) Sole power to dispose or to direct the disposition of: 3,320,000 shares of Common Stock.
	(iv) Shared power to dispose or to direct the disposition of: none
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Quick Capital, LLC

Signature:	/s/ Eilon Natan
Name/Title:	Eilon Natan/Managing Member
Date:	09/12/2025

FAQ

How many Regen BioPharma (RGBPP) shares does Quick Capital, LLC report owning?

3,320,000 shares, representing 9.9% of the outstanding common stock.

Does Quick Capital report shared voting or dispositive power over RGBPP shares?

No. The filing states Quick Capital has sole voting power and sole dispositive power for all reported shares.

Is Quick Capital filing as an activist seeking to change control of Regen BioPharma?

The filing is submitted as a Schedule 13G and includes a certification that the shares were not acquired to change or influence control of the issuer.

Is Quick Capital part of a group or does it hold the shares on behalf of another person?

No. The filing indicates no group affiliations and states ownership on behalf of another person is not applicable.

What type of entity is the reporting person for RGBPP?

The reporting person is Quick Capital, LLC, a Wyoming-organized limited liability company.